RT Journal Article
SR Electronic
T1 Neuronal Dysfunction and Medical Therapy in Heart Failure: Can an Imaging Biomarker Help to “Personalize” Therapy?
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 20S
OP 24S
DO 10.2967/jnumed.114.142778
VO 56
IS Supplement 4
A1 Benjamin S. Wessler
A1 James E. Udelson
YR 2015
UL http://jnm.snmjournals.org/content/56/Supplement_4/20S.abstract
AB 123I-metaiodobenzylguanidine (123I-MIBG) imaging is a tool for evaluating one of the fundamental pathophysiologic abnormalities seen in heart failure (HF), that of an upregulated sympathetic nervous system and its effect on the myocardium. Although this imaging technique offers information about prognosis for patients treated with contemporary guideline-based HF therapies and improves risk stratification, there are neither rigorous nor sufficient outcome data to suggest that this imaging tool can guide therapeutic decision making or better target subsets of patients with HF for particular therapies.